Skip to content
Open in App
Boston Scientific logo

Boston Scientific

web2

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in va...

Symbol · 1BSX
Company profile

About

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Definitive agreement to acquire Penumbra

KEY STEP

Boston Scientific announced a definitive agreement to acquire Penumbra in a cash and stock transaction valued at approximately $14.5 billion of enterprise value, expanding its cardiovascular portfolio into mechanical thrombectomy and neurovascular markets.

Roadmap reference
People

Company team

MF

Michael F. Mahoney

Chairman, President & CEO

Company leadership profile.

EM

Ellen M. Zane

Independent Director

Company leadership profile.

DS

David Scott Wichmann

Independent Director

Company leadership profile.

SE

Susan E. Morano

Independent Director

Company leadership profile.

CB

Cheryl B. Pegus

Independent Director

Company leadership profile.

EJ

Edward J. Ludwig

Lead Independent Director

Company leadership profile.

JL

Jessica L. Mega

Independent Director

Company leadership profile.

DC

David Cyril Habiger

Independent Director

Company leadership profile.

CR

Catherine R. Smith

Independent Director

Company leadership profile.

CP

Christophe P. Weber

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Boston Scientific.

Orbitrum research

Experts evaluating Boston Scientific

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment